EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardiac biomarkers in COVID-19: what did we learn?

Lara Srour, Jaafar Ismail iD, Rana Zareef, Mariam Arabi iD

Cardiology in the Young · 2024

DOI: 10.1017/s1047951124025484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiology in the Young, 2024. Verfasst von Lara Srour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Hauptthemen laut MEDLINE: COVID-19, Biomarkers, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

COVID-19, caused by the SARS-CoV-2 virus, has generated a global pandemic with a wide range of clinical manifestations. Cardiovascular complications are frequently observed in individuals with COVID-19, particularly those with preexisting cardiovascular risk factors or diseases. Cardiac biomarkers, including troponin, natriuretic peptides, and inflammatory markers, play a vital role in risk stratification, diagnosis, monitoring, and prognosis in COVID-19 patients. These biomarkers provide valuable insights into cardiac injury, myocardial stress, inflammation, and the prediction of adverse cardiovascular outcomes. This review aims to provide better understanding of how Cardiac biomarkers correlate to clinical manifestation of COVID-19.

Methods

We retrieved studies from PubMed, Medline, and Google Scholars that included results on cardiac biomarkers in COVID-19. Total of 14 studies were reviewed.

Results

8 studies showed evidence of poor progression of the disease when there is increased troponin. 6 studies out of the 14 mentioned in this review showed positive correlation between mortality and elevation in cardiac biomarkers. This shows the significance of cardiac biomarkers in predicting the mortality in patients with COVID-19.

Conclusion

It was shown that elevated cardiac biomarkers were associated significantly to poor outcome of covid-19 infection. The outcomes that were linked to increased cardiac biomarkers included increased length of hospitalization, need of life sustaining treatment, myocarditis, invasive and non-invasive respiratory support, and even death were linked to elevated cardiac biomarkers levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19BiomarkersCardiovascular DiseasesHumansTroponinPrognosisSARS-CoV-2

Stichwörter der Autor:innen

COVID-19SARS-CoV-2cardiac biomarkerscardiovascular complications

Substanzen

BiomarkersTroponin

Autor:innen und Institutionen

  • Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Department of Pediatrics and Adolescent Medicine, Division of Pediatric Cardiology, American University of Beirut Medical Center, Beirut, Lebanon.

ORCID-Profile: Jaafar Ismail, Mariam Arabi

Zitieren

APA

Srour, L., Ismail, J., Zareef, R., & Arabi, M. (2024). Cardiac biomarkers in COVID-19: what did we learn?. Cardiology in the Young. https://doi.org/10.1017/s1047951124025484

Vancouver

Srour L, Ismail J, Zareef R, Arabi M. Cardiac biomarkers in COVID-19: what did we learn?. Cardiology in the Young. 2024. doi:10.1017/s1047951124025484

BibTeX
@article{Srour2024,
  author = {Srour, Lara and Ismail, Jaafar and Zareef, Rana and Arabi, Mariam},
  title = {Cardiac biomarkers in COVID-19: what did we learn?},
  journal = {Cardiology in the Young},
  year = {2024},
  doi = {10.1017/s1047951124025484}
}
Kostenlos starten →